MA40344A - Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer - Google Patents
Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancerInfo
- Publication number
- MA40344A MA40344A MA040344A MA40344A MA40344A MA 40344 A MA40344 A MA 40344A MA 040344 A MA040344 A MA 040344A MA 40344 A MA40344 A MA 40344A MA 40344 A MA40344 A MA 40344A
- Authority
- MA
- Morocco
- Prior art keywords
- antagonist
- listeria
- combination
- prostate cancer
- based vaccine
- Prior art date
Links
- 241000186781 Listeria Species 0.000 title 1
- 229940124060 PD-1 antagonist Drugs 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne des polythérapies comprenant un antagoniste du récepteur de mort programmée 1 (pd -1) et une souche de listeria qui exprime un antigène spécifique des tissus de la prostate (psa), et l'utilisation de polythérapies pour le traitement du cancer de la prostate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462026221P | 2014-07-18 | 2014-07-18 | |
US201462039011P | 2014-08-19 | 2014-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40344A true MA40344A (fr) | 2016-01-21 |
Family
ID=55079087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040344A MA40344A (fr) | 2014-07-18 | 2015-07-17 | Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer |
Country Status (11)
Country | Link |
---|---|
US (2) | US9907849B2 (fr) |
EP (1) | EP3193921A4 (fr) |
KR (1) | KR20170052569A (fr) |
CN (2) | CN106999561A (fr) |
AU (1) | AU2015289533B2 (fr) |
CA (1) | CA2955612C (fr) |
IL (1) | IL250187B (fr) |
MA (1) | MA40344A (fr) |
MX (1) | MX2017000857A (fr) |
SG (2) | SG10201913696YA (fr) |
WO (1) | WO2016011357A1 (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
US8771702B2 (en) * | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
BRPI0812913B8 (pt) * | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
CA2829960A1 (fr) | 2011-03-11 | 2012-09-20 | John Rothman | Adjuvants a base de listeria |
JP2015511602A (ja) | 2012-03-12 | 2015-04-20 | アドバクシス, インコーポレイテッド | リステリアワクチン処理後のサプレッサー細胞機能抑制 |
BR112014028826B1 (pt) | 2012-05-15 | 2024-04-30 | Bristol-Myers Squibb Company | Uso de nivolumab ou pembrolizumabe |
JP6502959B2 (ja) | 2013-12-12 | 2019-04-17 | 上海恒瑞医薬有限公司 | Pd−1抗体、その抗原結合性断片及びそれらの医学的使用 |
BR112016019057A2 (pt) | 2014-02-18 | 2017-10-10 | Advaxis Inc | método de induzir uma resposta imune contra uma doença em um indivíduo |
CN106459887A (zh) | 2014-04-24 | 2017-02-22 | 阿德瓦希斯公司 | 重组李斯特菌疫苗菌株及其制备方法 |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
KR20170138555A (ko) | 2015-04-28 | 2017-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료 |
WO2016176504A1 (fr) * | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Traitement du mélanome pd-l1 positif à l'aide d'un anticorps anti-pd-1 |
KR20180040138A (ko) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법 |
EP3858859A1 (fr) * | 2015-07-14 | 2021-08-04 | Bristol-Myers Squibb Company | Méthode de traitement du cancer à l'aide de contrôle immunitaire ; anticorps qui se lie à une mort programmée-1 receptor (pd-1) ou mort programmée ligand 1 (pd-l1) |
WO2017106638A1 (fr) | 2015-12-16 | 2017-06-22 | Gritstone Oncology, Inc. | Identification de néogènes, fabrication et utilisation |
CA3013554A1 (fr) * | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Agents therapeutiques cibles et leurs utilisations |
AU2017217940B2 (en) | 2016-02-12 | 2024-03-21 | Madison Vaccines Inc. | Cancer therapy |
WO2018027524A1 (fr) | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Formule d'anticorps anti-pd-1. |
EP3548623A4 (fr) | 2016-11-30 | 2020-11-25 | Advaxis, Inc. | Compositions immunogènes ciblant des mutations récurrentes du cancer et leurs procédés d'utilisation |
TW201834639A (zh) * | 2017-03-06 | 2018-10-01 | 德商馬克專利公司 | 水性抗體調配物 |
SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
NZ759442A (en) | 2017-06-01 | 2024-07-05 | Cytomx Therapeutics Inc | Activatable anti-pdl1 antibodies, and methods of use thereof |
AU2018336988B2 (en) | 2017-09-19 | 2023-06-22 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or Listeria strains |
EP3694532A4 (fr) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | Identification de néo-antigènes au moyen de points chauds |
AU2018373154A1 (en) | 2017-11-22 | 2020-07-02 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
JP2021513541A (ja) * | 2018-02-13 | 2021-05-27 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗pd−1抗体によるがんの処置方法 |
US20210236545A1 (en) * | 2018-08-02 | 2021-08-05 | Suzhou Royaltech Med Co., Ltd | Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof |
WO2020033283A1 (fr) * | 2018-08-09 | 2020-02-13 | Merck Sharp & Dohme Corp. | Compositions et méthodes de traitement du cancer avec une association d'anticorps anti-récepteur de mort programmée (pd-1) et de vicriviroc |
US20210317214A1 (en) * | 2018-09-13 | 2021-10-14 | Merck Sharp & Dohme Corp. | Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancer |
EP3730153A1 (fr) | 2019-04-26 | 2020-10-28 | Medizinische Hochschule Hannover | Immunothérapie personnalisée pour le traitement du cancer |
US20220362308A1 (en) * | 2019-09-24 | 2022-11-17 | Novome Biotechnologies, Inc. | Oral administration of genetically engineered bacteria |
CN110898012B (zh) * | 2019-12-06 | 2021-08-10 | 北京大学 | 一种包载过氧化氢酶且连接pd-l1抗体的脂质体及其制备方法 |
CN116096920A (zh) | 2020-06-23 | 2023-05-09 | 科罗拉多大学董事会法人团体 | 用于诊断呼吸道病原体和预测covid-19相关结果的方法 |
WO2023211868A1 (fr) * | 2022-04-29 | 2023-11-02 | Merck Sharp & Dohme Llc | Formulations stables d'anticorps anti-ilt4 ou de fragments de liaison à l'antigène de ceux-ci en combinaison avec des anticorps anti-pd-1 et leurs procédés d'utilisation |
WO2024026253A1 (fr) * | 2022-07-25 | 2024-02-01 | Agensys, Inc. | Méthodes de traitement de patients atteints d'un cancer urothélial localement avancé ou métastatique avec des conjugués anticorps-médicament (cam) qui se lient à des protéines 191p4d12 en combinaison avec du pembrolizumab |
WO2024047585A2 (fr) * | 2022-08-31 | 2024-03-07 | Proviva Therapeutics (Hong Kong) Limited | Protéines de fusion anticorps-procytokine il-15 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0831854A4 (fr) | 1995-06-06 | 2001-01-24 | Isis Pharmaceuticals Inc | Oligonucleotides de grande purete chirale ayant des liaisons phosphorothioate |
US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
EP1860192A1 (fr) | 1996-09-17 | 2007-11-28 | Novartis Vaccines and Diagnostics, Inc. | Compositions et procédés de traitement de maladies intracellulaires |
GB9726555D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
JP2004500405A (ja) | 2000-03-29 | 2004-01-08 | ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア | 抗原の免疫原性を増強するための組成物および方法 |
US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
EP3287144A1 (fr) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Compositions immunostimulantes |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
WO2004072286A1 (fr) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specifique a pd-1 humain |
KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
ES2741730T3 (es) | 2008-05-19 | 2020-02-12 | Advaxis Inc | Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico |
US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
CA2735006A1 (fr) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Antagonistes de pd-1 et leurs procedes d'utilisation |
ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
CN102469782A (zh) | 2010-06-18 | 2012-05-23 | 哈洛资源公司 | 包含壳聚糖的固态共混物的制剂及方法 |
CA2829960A1 (fr) * | 2011-03-11 | 2012-09-20 | John Rothman | Adjuvants a base de listeria |
US9220776B2 (en) | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
KR20190133790A (ko) | 2011-08-01 | 2019-12-03 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
EP2817306B1 (fr) | 2012-02-21 | 2015-09-16 | Merck Patent GmbH | Dérivés cycliques de diaminopyrimidine comme inhibiteurs de la syk |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
WO2014106123A1 (fr) | 2012-12-27 | 2014-07-03 | Aduro Biotech, Inc. | Partenaires de fusion de type peptides signal favorisant l'expression de séquences antigéniques dans les bactéries du genre listeria et leurs procédés de préparation et d'utilisation |
-
2015
- 2015-07-17 MA MA040344A patent/MA40344A/fr unknown
- 2015-07-17 US US14/802,607 patent/US9907849B2/en not_active Expired - Fee Related
- 2015-07-17 KR KR1020177004528A patent/KR20170052569A/ko not_active Application Discontinuation
- 2015-07-17 SG SG10201913696YA patent/SG10201913696YA/en unknown
- 2015-07-17 EP EP15822334.7A patent/EP3193921A4/fr active Pending
- 2015-07-17 CA CA2955612A patent/CA2955612C/fr active Active
- 2015-07-17 CN CN201580049879.1A patent/CN106999561A/zh active Pending
- 2015-07-17 SG SG11201701149SA patent/SG11201701149SA/en unknown
- 2015-07-17 MX MX2017000857A patent/MX2017000857A/es unknown
- 2015-07-17 WO PCT/US2015/040916 patent/WO2016011357A1/fr active Application Filing
- 2015-07-17 CN CN202210236053.8A patent/CN114984228A/zh active Pending
- 2015-07-17 AU AU2015289533A patent/AU2015289533B2/en active Active
-
2017
- 2017-01-18 IL IL250187A patent/IL250187B/en active IP Right Grant
-
2018
- 2018-01-09 US US15/865,602 patent/US20180185483A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL250187A0 (en) | 2017-03-30 |
CA2955612A1 (fr) | 2016-01-21 |
CN114984228A (zh) | 2022-09-02 |
WO2016011357A1 (fr) | 2016-01-21 |
US20180185483A1 (en) | 2018-07-05 |
KR20170052569A (ko) | 2017-05-12 |
EP3193921A1 (fr) | 2017-07-26 |
CN106999561A (zh) | 2017-08-01 |
EP3193921A4 (fr) | 2018-04-25 |
US9907849B2 (en) | 2018-03-06 |
SG10201913696YA (en) | 2020-03-30 |
SG11201701149SA (en) | 2017-04-27 |
MX2017000857A (es) | 2017-10-11 |
IL250187B (en) | 2020-10-29 |
US20160022814A1 (en) | 2016-01-28 |
AU2015289533B2 (en) | 2021-04-01 |
AU2015289533A1 (en) | 2017-03-02 |
CA2955612C (fr) | 2022-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40344A (fr) | Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer | |
MX2016010082A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer. | |
IL270720A (en) | Combination of treatments for cancer treatment | |
MX2017015308A (es) | Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer. | |
PH12016501550B1 (en) | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer | |
PH12017501857A1 (en) | Pd-l1 antagonist combination treatments | |
IL249658A0 (en) | Methods of treating cancer using tigit inhibitors and anticancer agents | |
HK1251862A1 (zh) | 治療癌症的方法和組合物 | |
IL249065A0 (en) | Combination of treatments for cancer treatment | |
MX2016002273A (es) | Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib. | |
TW201613635A (en) | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer | |
IL265786A (en) | Materials and methods for increasing radiotherapy against cancer | |
MX2017011206A (es) | Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer. | |
IL273395A (en) | Combined therapies for cancer treatment | |
IL270511A (en) | Combined treatments using niraparib and pembrolizumab for the treatment of cancer | |
IL261047A (en) | Taf1 inhibitors for the therapy of cancer | |
HUE054673T2 (hu) | Rák kezelésére szolgáló eljárások és készítmények | |
EP3131552A4 (fr) | Méthodes de traitement du cancer à l'aide d'une polythérapie avec des inhibiteurs de la kinase tor | |
PT3609497T (pt) | Niraparib, acetato de abiraterona e prednisona para o tratamento do cancro da próstata | |
IL245861A0 (en) | Use of substances to treat drug-resistant tumors | |
ZA201900438B (en) | Combination therapies for treating cancer | |
EP3131550A4 (fr) | Méthodes de traitement du cancer au moyen d'une multithérapie à base d'un inhibiteur de la kinase tor | |
IL274866A (en) | Preparations and methods for the treatment of cancer | |
GB201417819D0 (en) | Agents for cancer therapy | |
GB201515213D0 (en) | Combination therapy for PD-L1 negative tumors |